Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest

Cancer Letters

Volumn 277, Issue 1, 2009, Pages 91-100

  Lam, T L ^a   Wong, G K Y ^a   Chong, H C ^a   Cheng, P N M ^c   Choi, S C ^a   Chow, T L ^c   Kwok, S Y ^a   Poon, R T P ^b   Wheatley, D N ^c   Lo, W H ^a   Leung, Y C ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c Bio Cancer Treatment International Limited   (Hong Kong)

Author keywords

Combination therapy; G2 M phase arrest; Hepatocellular carcinoma (HCC); Ornithine transcarbamylase; Recombinant human arginase

Indexed keywords

ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; ARGINOSUCCINATE LYASE; CITRULLINE; CYCLIN DEPENDENT KINASE; CYCLINE; FLUOROURACIL; LYASE; ORNITHINE CARBAMOYLTRANSFERASE; PEGYLATED RECOMBINANT HUMAN ARGINASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUXOTROPHY; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ARGINASE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CITRULLINE; CITRULLINEMIA; CYCLIN-DEPENDENT KINASE 2; CYCLINS; HUMANS; LIVER NEOPLASMS; MICE; ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY DISEASE; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 62249130842     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.031     Document Type: Article

References (58)

1. Curley S.A., Cusack Jr. J.C., Tanabe K.K., Stoelzing O., and Ellis L.M. Advances in the treatment of liver tumors. Curr. Prob. Surg. 39 (2002) 449-571
2. Ryder S.D. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52 Suppl. 3 (2003) iii1-iii8
3. Raoul J.L. Natural history of hepatocellular carcinoma and current treatment options. Semin. Nucl. Med. 38 (2008) S13-S18
4. Varela M., Sala M., Llovet J.M., and Bruix J. Treatment of hepatocellular carcinoma: is there an optimal strategy?. Cancer. Treat. Rev. 29 (2003) 99-104
5. Ascierto P.A., Scala S., Castello G., Daponte A., Simeone E., Ottaiano A., Beneduce G., De Rosa V., Izzo F., Melucci M.T., Ensor C.M., Prestayko A.W., Holtsberg F.W., Bomalaski J.S., Clark M.A., Savaraj N., Feun L.G., and Logan T.F. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J. Clin. Oncol. 23 (2005) 7660-7668
6. Cheng P.N., Lam T.L., Lam W.M., Tsui S.M., Cheng A.W., Lo W.H., and Leung Y.C. Pegylated recombinant human arginase (rhArg-peg5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 67 (2007) 309-317
7. Currie G.A., Gyure L., and Cifuentes L. Microenvironmental arginine depletion by macrophages in vivo. Brit. J. Cancer 39 (1979) 613-620
8. Gonzalez G.G., and Byus C.V. Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. Cancer Res. 51 (1991) 2932-2939
9. Izzo F., Marra P., Beneduce G., Castello G., Vallone P., De Rosa V., Cremona F., Ensor C.M., Holtsberg F.W., Bomalaski J.S., Clark M.A., Ng C., and Curley S.A. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J. Clin. Oncol. 22 (2004) 1815-1822
10. Morris Jr. S.M. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22 (2002) 87-105
11. Storr J.M., and Burton A.F. The effects of arginine deficiency on lymphoma cells. Brit. J. Cancer 30 (1974) 50-59
12. Sugimura K., Ohno T., Kusuyama T., and Azuma I. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res. 2 (1992) 191-196
13. Takaku H., Matsumoto M., Misawa S., and Miyazaki K. Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism. Jpn. J. Cancer Res. 86 (1995) 840-846
14. Cheng P.N., Leung Y.C., Lo W.H., Tsui S.M., and Lam K.C. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett. 224 (2005) 67-80
15. Ni Y., Schwaneberg U., and Sun Z.H. Arginine deiminase, a potential anti-tumor drug. Cancer Lett. 261 (2008) 1-11
16. Shen L.J., Lin W.C., Beloussow K., and Shen W.C. Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett. 191 (2003) 165-170
17. Gong H., Zolzer F., von Recklinghausen G., Rossler J., Breit S., Havers W., Fotsis T., and Schweigerer L. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem. Biophys. Res. Commun. 261 (1999) 10-14
18. Gong H., Zolzer F., von Recklinghausen G., Havers W., and Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 14 (2000) 826-829
19. Noh E.J., Kang S.W., Shin Y.J., Choi S.H., Kim C.G., Park I.S., Wheatley D.N., and Min B.H. Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. Int. J. Cancer 112 (2004) 502-508
20. Wheatley D.N., and Campbell E. Arginine catabolism, liver extracts and cancer. Pathol. Oncol. Res. 8 (2002) 18-25
21. Arellano M., and Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29 (1997) 559-573
22. Hartwell L.H., and Kastan M.B. Cell cycle control and cancer. Science 266 (1994) 1821-1828
23. Morgan D.O. Principles of CDK regulation. Nature 374 (1995) 131-134
24. Pardee A.B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA 71 (1974) 1286-1290
25. Pardee A.B. G1 events and regulation of cell proliferation. Science 246 (1989) 603-608
26. Philip R., Campbell E., and Wheatley D.N. Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. Brit. J. Cancer 88 (2003) 613-623
27. Scott L., Lamb J., Smith S., and Wheatley D.N. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br. J. Cancer 83 (2000) 800-810
28. Bowles T.L., Kim R., Galante J., Parsons C.M., Virudachalam S., Kung H.J., and Bold R.J. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int. J. Cancer 123 (2008) 1950-1955
29. Yoon C.Y., Shim Y.J., Kim E.H., Lee J.H., Won N.H., Kim J.H., Park I.S., Yoon D.K., and Min B.H. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int. J. Cancer 120 (2007) 897-905
30. Sugimura K., Kimura T., Arakawa H., Ohno T., Wada Y., Kimura Y., Saheki T., and Azuma I. Elevated argininosuccinate synthetase activity in adult T leukemia cell lines. Leukemia Res. 14 (1990) 931-934
31. Ensor C.M., Holtsberg F.W., Bomalaski J.S., and Clark M.A. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62 (2002) 5443-5550
32. Feun L., and Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin. Investig Drugs 15 (2006) 815-822
33. Lamb J., and Wheatley D.N. Single amino acid (arginine) deprivation induces G1 arrest associated with inhibition of cdk4 expression in cultured human diploid fibroblasts. Exp. Cell Res. 255 (2000) 238-249
34. Weissfeld A.S., and Rouse H. Arginine deprivation in KB cells. I. Effect on cell cycle progress. J. Cell Biol. 75 (1977) 881-888
35. Wheatley D.N., Scott L., Lamb J., and Smith S. Single amino acid (arginine) restriction: growth and death of cultured HeLa and human diploid fibroblasts. Cell Physiol. Biochem. 10 (2000) 37-55
36. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
37. Sherr C.J. D-type cyclins. Trends Biochem. Sci. 20 (1995) 187-190
38. Sherr C.J. D1 in G2. Cell Cycle 1 (2002) 36-38
39. Stacey D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol. 15 (2003) 158-163
40. Wolter F., Akoglu B., Clausnitzer A., and Stein J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J. Nutr. 131 (2001) 2197-2203
41. Bressac B., Galvin K.M., Liang T.J., Isselbacher K.J., Wands J.R., and Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 87 (1990) 1973-1977
42. Lin Y., Shi C.Y., Li B., Soo B.H., Mohammed-Ali S., Wee A., Oon C.J., Mack P.O., and Chan S.H. Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Ann. Acad. Med. Singapore 25 (1996) 22-30
43. Murakami Y., Hayashi K., and Sekiya T. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res. 51 (1991) 3356-3361
44. Knowles B.B., Howe C.C., and Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209 (1980) 497-499
45. Monjardino J.P., Fowler M.J., and Thomas H.C. Defective hepatitis B virus DNA molecules detected in a stable integration pattern in a hepatoma cell line, and in induced tumours and derived cell lines. J. Gen. Virol. 64 10 (1983) 2299-2303
46. Sarbassov D.D., Ali S.M., and Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17 (2005) 596-603
47. Smith E.M., and Proud C.G. cdc2-Cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent manner. EMBO J. 27 (2008) 1005-1016
48. Holland J.F., Frei M.I., Pizzorno G., and Cheng Y.C. Pyrimidine and Purine Antimetabolites (1997), Williams & Wilkins, London
49. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3 (2003) 330-338
50. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., and Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104 (1999) 263-269
51. Wang H.E., Wu H.C., Kao S.J., Tseng F.W., Wang Y.S., Yu H.M., Chou S.L., Yen S.H., and Chi K.H. Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell. Biochem. Pharmacol. 69 (2005) 617-626
52. Eichhorst S.T., Muller M., Li-Weber M., Schulze-Bergkamen H., Angel P., and Krammer P.H. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell Biol. 20 (2000) 7826-7837
53. Koike K., Takaki A., Tatsukawa M., Suzuki M., Shiraha H., Iwasaki Y., Sakaguchi K., and Shiratori Y. Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. Int. J. Oncol. 29 (2006) 1253-1261
54. Schulze-Bergkamen H., Fleischer B., Schuchmann M., Weber A., Weinmann A., Krammer P.H., and Galle P.R. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 6 (2006) 232
55. Jiang S., Song M.J., Shin E.C., Lee M.O., Kim S.J., and Park J.H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology 29 (1999) 101-110
56. Brenes O., Arce F., Gatjens-Boniche O., and Diaz C. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. Biomed. Pharmacother. 61 (2007) 347-355
57. Rosen O., Muller H.J., Gokbuget N., Langer W., Peter N., Schwartz S., Hahling D., Hartmann F., Ittel T.H., Muck R., Rothmann F., Arnold R., Boos J., and Hoelzer D. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Brit. J. Haematol. 123 (2003) 836-841
58. Yoshioka T., Wada T., Uchida N., Maki H., Yoshida H., Ide N., Kasai H., Hojo K., Shono K., Maekawa R., Yagi S., Hoffman R.M., and Sugita K. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res. 58 (1998) 2583-2587